

The impact of COVID-19 during pregnancy on maternal and neonatal outcomes: a systematic review

Despoina Michailidou¹, Androniki Stavridou¹, Eleni D. Panagouli¹, Theodoros N. Sergentanis¹, Theodora Psaltopoulou², Flora Bacopoulou^{3✉}, Valentina Baltag⁴, Donald E. Greydanus⁵, George Mastorakos⁶, George Chrousos³, Maria N. Tsolia¹, Artemis K. Tsitsika¹, Nikolaos Vlahos⁶

¹Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece

²Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

³University Research Institute of Maternal and Child Health & Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Athens, Greece

⁴Department of Maternal, Newborn, Child & Adolescent Health & Ageing, World Health Organization

⁵Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker M.D. School of Medicine, United States

⁶Second Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, School of Medicine, Aretaieion Hospital, Athens, Greece

Competing interests: DM none; AS none; EDP none; TNS none; TP none; FB none; VB none; DEG none; GM none; GPC none; MNT none; AKT none; NV none

Abstract

Several months after the onset of the epidemic, COVID-19 remains a global health issue. Scientific data on pregnancy, perinatal outcomes and vertical transmission of SARS-CoV-2 are constantly emerging but are still limited and unclear. The purpose of this systematic review was to summarize current evidence on vertical transmission rates, maternal, perinatal and neonatal outcomes and mode of delivery in pregnancies affected by COVID-19. An extensive search was conducted in PubMed, Google Scholar, Embase, and Scopus databases up to June 20, 2020. A total of 133 articles (51 case reports, 31 case series, 40 cohort studies and 2 case-control studies) reporting data from 8,092 subjects (6,046 pregnant women and 2,046 neonates) were considered eligible for inclusion in the systematic review. A substantial proportion of pregnant women with COVID-19 underwent caesarean section (case reports 82.2%, case series 74.2% and cohort studies 66.0%). Regarding vertical transmission, most neonates were tested negative (case reports 92.7%, case series studies 84.2%, cohort studies 97.1% and case control studies 100%). Maternal mortality rates ranged from 1% in cohort studies to 5.7% in case reports; neonatal mortality ranged from 2% in case reports to 3.3% in case series. Vertical transmission of SARS-CoV-2 from mother to child is rare. Careful screening of pregnant women seems important and specific guidelines with evidence-based decision algorithms for the mode of delivery in the context of a pregnancy affected by COVID-19 should be established.

Introduction

Coronavirus disease (COVID-19) is caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and was first described in Wuhan, China in December of 2019 (Jin *et al.*, 2020). COVID-19 was declared by the World Health Organization as pandemic on March 11, 2020 (Ng *et al.*, 2020) and can result in severe pneumonia, multi-organ failure and death (Hui *et al.*, 2020). Over the last twenty years, two large epidemics

of coronaviruses have been recorded, the SARS (Severe Acute Respiratory Syndrome) epidemic with a case fatality rate about 10.5% (WHO) and the MERS (Middle East Respiratory Syndrome) epidemic with a case fatality rate of 34.3% (WHO). According to the literature, the infections caused from SARS and MERS coronaviruses have been associated with serious maternal and neonatal morbidity and mortality, stillbirth and high percentage of spontaneous abortion (Schwartz and Graham, 2020; Wong *et al.*, 2004). The epidemiological data from China

Article history

Received: 29 October 2020

Accepted: 23 November 2020

Published: October 2021

© 2021 Michailidou *et al.*; the authors have retained copyright and granted the Journal right of first publication; the work has been simultaneously released under a Creative Commons Attribution Licence, which allows others to share the work, while acknowledging the original authorship and initial publication in this Journal. The full licence notice is available at <http://journal.embnet.org>.

about COVID-19 have shown that most cases had mild symptoms with a case fatality rate about 2.3%. SARS-CoV-2 seems to be more contagious on close contacts (Wu and McGoogan, 2019), albeit less aggressive than the aforementioned two coronaviruses.

Pregnancy is considered a state of relative immunological suppression, with a reduction in cellular immunity and potential susceptibility to infections (Birkeland and Kristoffersen, 1980; Goodnight and Soper, 2005); changes in hormonal levels, such as beta human chorionic gonadotropin (β -hCG), progesterone and cortisol may mediate pregnancy-related cellular immunity immunosuppression. Additionally, the increase in uterine size causes the diaphragm to rise by 4 cm, enlarging the transverse diameter of the chest by 2 cm and affecting pulmonary volume. On the other hand, the immaturity of the immune system of fetuses and neonates makes them more vulnerable to infections (van Well *et al.*, 2017). Therefore, pregnant women and neonates could be considered a high-risk group for infection during the present pandemic.

Scientific data on pregnancy, perinatal outcomes and vertical transmission of SARS-CoV-2 are rather limited but rapidly accumulating. Over the past months, case reports and cohort studies have reported variable results on the mode of delivery, perinatal outcomes, vertical transmission from mother to infant or intrauterine transmission, and treatment modalities (Lang and Zhao, 2020; Martinelli *et al.*, 2020; Ahmed *et al.*, 2020; Liu W *et al.*, 2020). The purpose of this systematic review was to summarize current evidence on vertical transmission rates, maternal, perinatal and neonatal outcomes and mode of delivery in pregnancies affected by COVID-19.

Materials, Methodologies and Techniques

Study design

The present systematic review was performed according to the PRISMA guidelines (Liberati *et al.*, 2009). A search was performed in PubMed, Google Scholar, Embase, and Scopus databases up to June 20, 2020. The following search terms were used: (Covid-19 OR COVID-19 OR SARS-CoV-2 OR “2019-nCoV” OR “novel coronavirus”) AND (gestation OR pregnancy OR pregnant OR gestational OR neonate OR neonatal). Additionally, references of all articles were checked thoroughly.

Inclusion criteria

Only original research articles (cohort studies, cross-sectional studies, case-control studies, case series and case reports) published in the English language were included. Studies referring to pregnancies and/or deliveries of all ages with maternal confirmed COVID-19, with reverse transcription polymerase chain reaction (RT-PCR) and/or positive computed tomography (CT) findings, were deemed eligible. No limitations, such as ethnicity or journal, were considered. Studies with overlapping populations were excluded.

Eligibility assessment and risk of bias assessment

The retrieved studies were screened by three reviewers independently (D.M., A.S. and E.P.). The Newcastle-Ottawa Quality Scale (Ottawa Hospital Research Institute) was used to evaluate the quality of the studies. If there was a disagreement, team consensus followed.

Data extraction

Three authors (D.M, A.S. and E.P.) extracted all relevant data. General information, such as first author's name, location or country, study design, study period, number of participants (pregnancies or neonates), maternal age, gestational age, mode of delivery, treatment, co-morbidity of the mother, maternal and neonatal outcomes and test for COVID-19 were recorded. Data were tabulated; frequencies and percentages for categorical variables were estimated.

Results

Selection of studies

After search in the databases, a total of 666 articles were retrieved. The flow chart describing the selection of studies is presented in Figure 1.

After removal of duplicates, 354 items were selected for extensive review. Out of them, 162 articles were excluded as irrelevant to the topic and 42 articles as reviews (15 systematic reviews and 27 reviews). The remaining 150 full-text articles were subjected to further consideration; of them, 17 articles were excluded because of language (eleven in Chinese, four in French, and two in Spanish). Finally, 133 articles were included in the systematic review (Wang S *et al.*, 2020; Dong L *et al.*, 2020; Wen *et al.*, 2020; Lee *et al.*, 2020; Kalafat *et al.*, 2020; Chen R, Chen *et al.*, 2020; Peng *et al.*, 2020; Lowe and Bopp, 2020; Xiong *et al.*, 2020; Wang *et al.*, 2020; Li *et al.*, 2020; Lang and Zhao, 2020; Schnettler *et al.*, 2020; Iqbal *et al.*, 2020; Piersigilli *et al.*, 2020; Taghizadieh *et al.*, 2020; Xia *et al.*, 2020; Lu *et al.*, 2020; Hong *et al.*, 2020; Blauvelt *et al.*, 2020; Lyra *et al.*, 2020; Kelly *et al.*, 2020; Martinelli *et al.*, 2020; Du *et al.*, 2020; Bani *et al.*, 2020; Rabice *et al.*, 2020; AlZaghal *et al.*, 2020; Nesr *et al.*, 2020; Carosso *et al.*, 2020; Yu *et al.*, 2020; Oh *et al.*, 2020; Kuhrt *et al.*, 2020; Ahmed *et al.*, 2020; Kirtsman *et al.*, 2020; Mehta *et al.*, 2020; Anderson *et al.*, 2020; Dong Y *et al.*, 2020; De Socio *et al.*, 2020; Yilmaz *et al.*, 2020; Baud *et al.*, 2020; Fontanella *et al.*, 2020; Gidlöf *et al.*, 2020; Alonso Díaz *et al.*, 2020; Liao X *et al.*, 2020; Mohammadi *et al.*, 2020; Sinkey *et al.*, 2020; Panichaya *et al.*, 2020; Zamaniyan *et al.*, 2020; Zambrano *et al.*, 2020; Liao *et al.*, 2020; Liu *et al.*, 2020; Yu *et al.*, 2020; Chen *et al.*, 2020; Zhu *et al.*, 2020; Fan *et al.*, 2020; Zeng *et al.*, 2020; Yang *et al.*, 2020; Chen *et al.*, 2020; Vlachodimitropoulou *et al.*, 2020; Khan *et al.*, 2020; Buonsenso *et al.*, 2020; Wu C *et al.*, 2020; Hu *et al.*, 2020; Hantoushzadeh *et al.*, 2020; Baergen and Heller, 2020; Buonsenso *et al.*, 2020;




Figure 1. PRISMA flow chart of included studies.

Yu *et al.*, 2020; Juusela *et al.*, 2020; Silverstein *et al.*, 2020; Yassa *et al.*, 2020a; Lucarelli *et al.*, 2020; Govind *et al.*, 2020; Cooke *et al.*, 2020; Dória *et al.*, 2020; Xu *et al.*, 2020; Cao *et al.*, 2020; Andrikopoulou *et al.*, 2020; Huang *et al.*, 2020; McLaren *et al.*, 2020; Breslin *et al.*, 2020; Chen R, Zhang, *et al.*, 2020; Liu H *et al.*, 2020; Liu *et al.*, 2020; Yan *et al.*, 2020; Wu Y *et al.*, 2020; Shanes *et al.*, 2020; Ferrazzi *et al.*, 2020; Penfield *et al.*, 2020; Collin *et al.*, 2020; Qadri and Mariona, 2020; Qiancheng *et al.*, 2020; Wu Xiaoqing *et al.*, 2020; Pierce-Williams *et al.*, 2020; Yang H *et al.*, 2020; Kayem *et al.*, 2020; Knight *et al.*, 2020; Khalil *et al.*, 2020; Chen L, Li, *et al.*, 2020; Lokken *et al.*, 2020; Liao J *et al.*, 2020; London *et al.*, 2020; Patanè *et al.*, 2020; Savasi *et al.*, 2020; Pereira *et al.*, 2020; Khoury *et al.*, 2020; Zeng Y *et al.*, 2020; Sentilhes *et al.*, 2020; Zeng Q-L *et al.*, 2020; Mendoza *et al.*, 2020; Wang Z *et al.*, 2020; Martínez-Perez *et al.*, 2020; Miller *et al.*, 2020; Blitz *et al.*, 2020; Fox and Melka, 2020; Campbell *et al.*, 2020; Emeruwa *et al.*, 2020; Gagliardi *et al.*, 2020; Goldfarb *et al.*, 2020; Li N *et al.*, 2020; Tekbali *et al.*, 2020; Sutton *et al.*, 2020; Fassett *et al.*, 2020; RCOG; Ashokka *et al.*, 2020; Zaigham and Andersson, 2020; Juan *et al.*, 2020; Kotabagi *et al.*, 2020; Ifdil *et al.*, 2020; Zeng L-N *et al.*, 2020; Masjoudi *et al.*, 2020; Wu Yanting *et al.*, 2020; Lee T-Y *et al.*, 2020; Suzuki 2020; Huang J-W *et al.*, 2020; Berthelot *et al.*, 2020; Durankuş and Aksu, 2020). Among them 51 were case reports (100 patients, 52 pregnant women and 48 neonates), 31 case series (390 patients, 211 pregnant women and 179 neonates), 40 cohort studies (4,474 patients, 2,685 pregnant women and 1,789 neonates) and 2 case-control studies (3,128 patients, 3,098 pregnant women and 30 neonates). A total of 8,092 patients, 6,046 pregnant women and 2,046 neonates were included in the systematic review.

Case reports

Demographics in case reports: The 51 case reports (Wang S *et al.*, 2020; Dong L *et al.*, 2020; Alzamora *et al.*, 2020; Wen *et al.*, 2020; Lee DH *et al.*, 2020; Kalafat *et al.*, 2020; Chen R., Chen, *et al.*, 2020; Li Y *et al.*, 2020; Peng *et al.*, 2020; Lowe and Bopp, 2020; Xiong *et al.*, 2020; Wang X *et al.*, 2020; Li J *et al.*, 2020; Lang and Zhao, 2020; Schnettler *et al.*, 2020; Iqbal *et al.*, 2020; Piersigilli *et al.*, 2020; Taghizadieh *et al.*, 2020; Xia *et al.*, 2020; Lu *et al.*, 2020; Hong *et al.*, 2020; Blauvelt *et al.*, 2020; Lyra *et al.*, 2020; Kelly *et al.*, 2020; Martinelli *et al.*, 2020; Du *et al.*, 2020; Bani Hani *et al.*, 2020; Rabice *et al.*, 2020; AlZaghal *et al.*, 2020; Nesr *et al.*, 2020; Carosso *et al.*, 2020; Yu Y *et al.*, 2020; Oh *et al.*, 2020; Kuhrt *et al.*, 2020; Ahmed *et al.*, 2020; Kirtsman *et al.*, 2020; Mehta *et al.*, 2020; Anderson *et al.*, 2020; DongY. *et al.*, 2020; De Socio *et al.*, 2020; Yilmaz *et al.*, 2020; Baud *et al.*, 2020; Fontanella *et al.*, 2020; Gidlöf *et al.*, 2020; Alonso Díaz *et al.*, 2020; Liao X *et al.*, 2020; Mohammadi *et al.*, 2020; Sinkey *et al.*, 2020; Panichaya *et al.*, 2020; Zamaniyan *et al.*, 2020; Zambrano *et al.*, 2020) identified 52 pregnant women (mean ± SD; age 29.7 ± 9.1 years; gestational age 33.1 ± 6.3 weeks) from January 2020 to May 2020. The characteristics of case reports are summarized in Table 1 in [Supplementary Data](#)¹. The cases derived mostly from China (n=15), with US being the second most frequent location (n=11), followed by Italy, UK, Iran, Jordan, and Turkey (n=3), while Korea, Honduras, Sweden, Peru, Australia, Thailand, Spain, Switzerland, Portugal, Belgium, contributed one case each. All women presented to the emergency room for respiratory complications. Among them, 29 women had co-morbid health conditions, *i.e.* gestational diabetes (n=9), obesity (n=9), hypothyroidism (n=5), hypertension (n=3), asthma (n=2), thalassemia (n=1), myotonic dystrophy (n=1), pneumonia (n=1), respiratory failure (n=1), HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome (n=1), hepatitis B (n=1), thyroidectomy (n=1), immune thrombocytopenia (ITP) (n=1) and cholecystitis (n=1). All 52 pregnant women had COVID-19, confirmed either through RT-PCR or RT-PCR and CT scans.

Data about delivery in case reports: From the 52 pregnant women, 45 delivered (86%, 45/52) with caesarean section (C-section) (82.2%, 37/45); 7 delivered (15.6%, 7/45) by vaginal route. In one case the mode of delivery was not reported (2.2%, 1/45). From the remaining cases, one had a miscarriage (2%, 1/52), one pregnancy was terminated due to fetal Down syndrome (2%, 1/52) and in 5 cases pregnancy was still on-going or delivery was not reported (10%, 5/52). Fetal distress (19.5%, 7/37), respiratory distress/dyspnea of the mother and pneumonia due to COVID-19 (16.7%, 6/37) and preeclampsia (5.6%, 2/37) were the most common indications for C-section delivery (Table 1

¹http://journal.embnet.org/index.php/embnetjournal/article/downloadSuppFile/969/969_supp_1

in [Supplementary Data¹](#). In 12 cases the reason for C-section was not reported (12/37, 37.5%).

Therapeutic management in case reports: Thirty-seven (71.1%, 37/52) women received medication, including hydroxychloroquine (27%, 10/37), azithromycin (27%, 10/37), oseltamivir (16.2%, 6/37), ceftriaxone (13.5%, 5/37), O₂ support (13.5%, 5/37), lopinavir (8.1%, 3/37), corticosteroids (without information about the specific agent administered) (13.5%, 5/37), methylprednisolone (8.1%, 3/37), dexamethasone (5.4%, 2/37), remdesivir (5.4%, 2/37), interferon (5.4%, 2/37), oxytocin (2.7%, 1/37) and plasma (2.7%, 1/37). Administration of antivirals (18.9%, 7/37) and antibiotics (21.6%, 8/37) without any other specification were also reported. Due to COVID-19 complications 13 pregnant women were admitted to intensive care unit (ICU) (25% admission rate, 13/52) (Table 1 in [Supplementary Data¹](#)).

Neonatal and maternal outcomes in case reports:

A total of 48 neonates were born from the 45 deliveries, including 3 pairs of twins (12.5%, 6/48). The majority of neonates were tested negative for SARS-CoV-2 (84.3%, 32/38), 6 (15.7%, 6/38) were positive for the virus, while for 10 neonates it was not mentioned whether they were tested or not (20.9%, 10/48). Thirty-two neonates were considered healthy (66.6%, 32/48), while 10 were admitted to neonatal intensive care unit (NICU) (20.8%, 10/48) due to prematurity (20%, 2/10), feeding difficulties (10%, 1/10) and precautionary measures for COVID-19 (70%, 7/10). One death was reported 2 hours after birth (2%, 1/48) probably due to maternal COVID-19 and rapid deterioration of her health.

Concerning mother's health, 10 pregnant women (19.2%, 10/52) were in good condition after hospitalization, 13 were discharged (25%, 13/52), 3 were still hospitalized (5.7%, 3/52) and 3 (5.7%, 3/52) succumbed to COVID-19 complications (Table 1 in [Supplementary Data¹](#)).

Case series

Demographics in case series: From the 31 case series, 16 derived from China, 5 from New York City, 2 from Italy, 2 from the UK, 2 from New Jersey, and 1 from Canada, Iran, Portugal and Turkey, respectively, as presented in Table 2 in [Supplementary Data¹](#) (Chen S, *et al.*, 2020; Liu Y *et al.*, 2020; Yu N *et al.*, 2020; Chen H *et al.*, 2020; Zhu *et al.*, 2020; Fan *et al.*, 2020; Zeng L *et al.*, 2020; Yang P *et al.*, 2020; Chen Y., Peng, *et al.*, 2020; Vlachodimitropoulou Koumoutsea *et al.*, 2020; Khan *et al.*, 2020; Buonsenso *et al.*, 2020; Wu C *et al.*, 2020; Hu *et al.*, 2020; Hantoushzadeh *et al.*, 2020; Baergen and Heller, 2020; Buonsenso D *et al.*, 2020; Yu N, Li, Kang, Zeng, *et al.*, 2020; Juusela *et al.*, 2020; Silverstein *et al.*, 2020; Yassa *et al.*, 2020a; Lucarelli *et al.*, 2020; Govind *et al.*, 2020; Cooke *et al.*, 2020; Dória *et al.*, 2020; Xu *et al.*, 2020; Cao *et al.*, 2020; Andrikopoulou *et al.*, 2020; Huang W *et al.*, 2020; Breslin *et al.*, 2020). The 31 case series identified 211 pregnant women (mean \pm SD; age 31.4 \pm 5.5 years; gestational age 35.7 \pm 3.8 weeks). Concerning women's medical history, diabetes (n=18), hypertension

(n=15), asthma (n=6), anemia (n=4), hypoxia (n=3), hypothyroidism (n=2), influenza (n=1), polycystic ovary syndrome (n=1), gestational cholecystitis (n=1), placenta previa (n=1), septic shock (n=1), hepatitis B (n=1), anorexia (n=1), vaginal bleeding (n=1), psoriasis (n=1), scoliosis (n=1), severe myopia (n=1) and liver dysfunction (n=1) were recorded (Table 2 in [Supplementary Data¹](#)). All 211 women were confirmed COVID-19 cases through RT-PCR or presented positive findings in CT.

Data about delivery in case series: From 211 pregnant women, 83% (175/211) gave birth, while the remaining were still pregnant during the study period. Concerning the mode of delivery, 130 women (74.2%, 130/175) were subjected to C-section and 45 women (25.8%, 45/175) delivered through vaginal route. The most common indication for C-section was COVID-19 pneumonia (25.4%, 33/130), followed by fetal distress (10%, 13/130) and pre-eclampsia (6.9%, 9/130), while indications were not reported in 43.1% of cases (Table 2 in [Supplementary Data¹](#)).

Therapeutic management in case series: During hospitalization, information about treatment was provided for 70 out of 211 cases (33.2%); in the other 66.8% of cases, treatment-related information was not reported. Hydroxychloroquine (28.5%, 20/70), azithromycin (25.7%, 18/70), lopinavir/ritonavir (21.4%, 15/70), oseltamivir (14.2%, 10/70), ceftriaxone (12.8%, 9/70), and methylprednisolone (7.1%, 5/70) were administered more often. Most women were treated with antivirals and antibiotics and 29 of them (41.4%, 29/70) needed O₂ support; 24 women were transferred to ICU (11.4%, 24/211) due to respiratory deterioration and COVID-19 complications (Table 2 in [Supplementary Data¹](#)).

Neonatal and maternal outcomes in case series:

A total of 179 neonates were born, including 4 pairs of twins (4.5%, 8/179); 173 were born alive and 6 died (3.3% 6/179). Causes of deaths included refractory shock, multiple organ failure, intrauterine fetal death (n=2) and pre-eclampsia (n=2) of the mother. In many cases neonates were tested for SARS-CoV-2 shortly after birth; 101 were negative (92.7%, 101/109) and 8 were positive (7.3%, 8/109). 70 neonates were not tested or no test was reported (43.6%, 70/179). Most of the neonates were healthy, with some exceptions including fetal growth restriction (n=7), premature rupture of membranes (PROM) (n=3), respiratory distress syndrome (RDS) (n=2), mild pneumonia (n=2), fever (n=1), tachypnea (n=1), asphyxia (n=1), fetal growth discordance (n=1), spontaneous bowel perforation (n=1), talipes (n=1), pyrexia (n=1), cyanosis (n=1) and admission to NICU (n=11) due to precautionary measures for COVID-19 and prematurity (Table 2 in [Supplementary Data¹](#)).

Nine pregnant women presented pneumonia, with respiratory symptoms in most cases (4.3%, 9/211). Twenty-six women were in good health (26.5%, 56/211), twenty-eight were discharged from hospital (13.3%, 28/211), while no data were reported regarding the health of 105 women (49.7%, 105/211). Some women

needed more care, including ventilator support (n=1), support by extracorporeal membrane oxygenation (ECMO) (n=1), ICU (n=1) and re-admission (n=3) in hospital. Seven deaths were reported in mothers (3.3%, 7/211) due to COVID-19 complications (Table 2 in [Supplementary Data¹](#)).

Cohort Studies

Demographics in cohort studies: The 40 cohort studies identified 5,242 pregnant women, from which 2,685 (51% 2,685/5,242) were confirmed cases of COVID-19 through RT-PCR or CT scan (Table 3 in [Supplementary Data¹](#)) and were included in the present study (Chen *et al.*, 2020; Liu *et al.*, 2020; Liu *et al.*, 2020; Liu *et al.*, 2020; Yan *et al.*, 2020; Wu *et al.*, 2020; Shanes *et al.*, 2020; Ferrazzi *et al.*, 2020; Penfield *et al.*, 2020; Collin *et al.*, 2020; Qadri and Mariona, 2020; Qiancheng *et al.*, 2020; Wu *et al.*, 2020; Pierce-Williams *et al.*, 2020; Yang *et al.*, 2020; Kayem *et al.*, 2020; Knight *et al.*, 2020; Khalil *et al.*, 2020; Chen *et al.*, 2020; Lokken *et al.*, 2020; Liao *et al.*, 2020; London *et al.*, 2020; Patanè *et al.*, 2020; Savasi *et al.*, 2020; Pereira *et al.*, 2020; Khoury *et al.*, 2020; Zeng Y *et al.*, 2020; Sentilhes *et al.*, 2020; Zeng Q-L *et al.*, 2020; Mendoza *et al.*, 2020; Wang *et al.*, 2020; Martínez-Perez *et al.*, 2020; Miller *et al.*, 2020; Blitz *et al.*, 2020; Fox and Melka, 2020; Campbell *et al.*, 2020; Emeruwa *et al.*, 2020; Gagliardi *et al.*, 2020; Goldfarb *et al.*, 2020). The age range of women was 18-41 years and the gestational age ranged from 5 to 40 weeks. The majority of studies derived mainly from China (35%, 14/40) and US (35%, 14/40), 4 from Italy (10%, 4/40), 3 from Spain (7.5%, 3/40), 2 from UK (5%, 2/40), 2 from France (5%, 2/40) and 1 from Sweden (2.5%, 1/40), as shown in Table 3 in [Supplementary Data¹](#). Co-morbidities were reported in 249 pregnant women and included gestational diabetes (22.8%, 57/249), obesity (21.6%, 54/249), hypertension (20.8%, 52/249), hypothyroidism (14.4 %, 36/249), asthma (8.0%, 20/249), and hepatitis B (2%, 5/249).

Data about delivery in cohort studies: In cohort studies, 1,789 neonates were born, including 3 pairs of twins (0.3%, 6/1789) from 1,786 pregnancies. In 378 cases the delivery mode was not mentioned; in the remaining 1,408 pregnancies 929 C-sections (66.0%, 929/1,408) and 479 vaginal deliveries were reported (34.0%, 479/1408). Indicators for C-section were mainly related to COVID-19 symptoms (8.1%, 75/929), fetal distress (3.6%, 34/929) and fetal heart complications (2.4%, 23/929) (Table 3 in [Supplementary Data¹](#)).

Therapeutic management in cohort studies: Treatment details were recorded in 1,267 cases; 25.8% (327/1,267) of pregnant women received antiviral therapy, 18.2% (231/1,267) O2 support, 19.7% (250/1,267) antibiotics, 16.2 % (206/1,267) corticosteroids, 6.4% (82/1,267) hydroxychloroquine, 2.2% (29/1,267) remdesivir, 1.6% (21/1,267) azithromycin, 1%, (13/1,267) interleukin-6 inhibitors, 1%, (13/1,267) convalescent plasma, 0.6% (8/1,267) oseltamivir, 0.3% (4/1,267)

lopinavir/ritonavir, and 46 were admitted to ICU (3.6%, 46/1,267) (Table 3 in [Supplementary Data¹](#)).

Neonatal and maternal outcomes in cohort studies: The health status was reported in 316 neonates from a total of 1,789 cases, with 62.2% being admitted to neonatal intensive care unit (NICU) (197/316), 18.6% being completely healthy (59/316), 15.8% being discharged from hospital shortly after birth (50/316), 0.3% presenting with pneumonia (1/316) and 0.3% remaining in hospital (1/316). Neonatal deaths were reported in 2.5% of cases (8/316); five due to COVID-19 (5/316, 1.6%), one to neonatal asphyxia, one to prematurity and one to intrauterine fetal death (IUFD). The majority of neonates (97.1%, 698/719) were tested negative for SARS-CoV-2; 21 were tested positive (2.9%, 21/719); the remaining 1,070 were either not tested or relevant data were not reported (59.8%, 1,070/1,789) (Table 3 in [Supplementary Data¹](#)).

Maternal health outcome was reported in 779 cases. Forty-four pregnant women remained hospitalized (5.6%, 44/779) during the study period, 80.6% were discharged (629/779) and 12.3% were in good health (96/779). One woman needed ventilation and one plasmapheresis. Eight women died (1%, 8/779), due to COVID-19 complications, multiple organ failure and severe respiratory distress (Table 3 in [Supplementary Data¹](#)).

Case-control studies

Two case-control studies were identified (Li N *et al.*, 2020; Tekbali *et al.*, 2020). One study in New York City, in March 2020, compared 3,064 pregnant with 18,916 non-pregnant control women concerning COVID-19-related admission to hospitals. The rates of admission of pregnant/postpartum and control women increased from week 1 to week 4 of the COVID-19 outbreak from 0.14% to 5.65% and from 1.21% to 56.79%, respectively (Table 4 in [Supplementary Data¹](#)).

Another study, conducted in Wuhan, in January to February 2020, compared 34 pregnant women with COVID-19 (n=16) or suspected COVID-19 (n=18) with 121 pregnant women without COVID-19 and 121 pregnant women who had been admitted for other reasons in the past (2019). The COVID-19 group gave birth to 30 neonates (all via C-section) and the control group to 101 neonates (all via C-section). Concerning the health of the pregnant women, three presented with gestational diabetes (8.8%, 3/34), three with gestational hypertension (8.8%, 3/34), one with hypothyroidism (2.9%, 1/34), one with sinus tachycardia (2.9%, 1/34) and one with pre-eclampsia (2.9%, 1/34), and were all discharged home. The main therapeutic treatment administered was antibiotics (100%, 34/34) and antivirals (11.7%, 4/34). No complications in neonatal health were mentioned and all neonates were negative for SARS-CoV-2 (n=30) (Table 4 in [Supplementary Data¹](#)).

Risk of bias: According to Newcastle-Ottawa scale ratings the majority of the 40 cohort studies were

identified as good or fair quality studies (11/40 and 17/40, respectively). Eleven studies were scored as poor quality (Breslin *et al.*, 2020; McLaren *et al.*, 2020; Liu H *et al.*, 2020; Liu W *et al.*, 2020; Ferrazzi *et al.*, 2020; Khalil *et al.*, 2020; Chen L *et al.*, 2020; Lokken *et al.*, 2020; Martínez-Perez *et al.*, 2020; Miller *et al.*, 2020). Short follow-up period was the most prominent factor compromising the quality of studies. Most studies presented clear inclusion criteria, with detailed description of the sample (pregnant women exposed to SARS-CoV-2, randomly selected) while data were derived from reliable, hospital records. Unadjusted (univariate) estimates were provided as a rule; almost half of the studies included a non-exposed group that matched with the exposed group in factors, such as age, gestational age, delivery mode and comorbidities. In the studies of poor quality, there was no description of the non-exposed group or any comparison with the exposed one.

Discussion

COVID-19 is a global health issue, several months after the onset of the outbreak. Pregnant women are considered a high risk group, not only physically, but psychologically as well (Birkeland and Kristoffersen, 1980; Goodnight and Soper, 2005; Kotabagi *et al.*, 2020; Ifdil *et al.*, 2020; Zeng L-N *et al.*, 2020; Masjouidi *et al.*, 2020; Wu, Zhang *et al.*, 2020; Lee T-Y *et al.*, 2020; Suzuki, 2020; Huang J-W *et al.*, 2020; Berthelot *et al.*, 2020; Durankuş and Aksu, 2020; Yassa *et al.*, 2020b; Corbett *et al.*, 2020). As new data concerning the virus and its transmission are constantly emerging, the present systematic review comprises various types of studies and a considerably larger sample (8,092 patients, 6,046 pregnant women and 2,046 neonates) compared to previous efforts.

There has been a great controversy concerning the vertical transmission of SARS-CoV-2 between positive mothers and embryos. In the present systematic review, the majority of neonates were tested negative (case reports 92.7%, case series studies 84.2%, cohort studies 97.1% and case control studies 100%), while all mothers were tested positive. Our findings are in line with the literature (Dong L *et al.*, 2020; Carosso *et al.*, 2020; Kirtsman *et al.*, 2020; Zeng L *et al.*, 2020; Ferrazzi *et al.*, 2020; Kayem *et al.*, 2020) supporting that vertical transmission does not occur in the majority of neonates (Wang S *et al.*, 2020; Dong L *et al.*, 2020; Wen *et al.*, 2020; Wang X *et al.*, 2020; Bani Hani *et al.*, 2020; Rabice *et al.*, 2020), as there are only a few reports of potential transplacental transmission of the virus (Vivanti *et al.*, 2020). Most studies have shown that there were no clinical findings of COVID-19 in neonates born to affected mothers and all samples concerning amniotic fluid, cord blood, placentas and breast milk, were negative (Chen S., Liao, *et al.*, 2020; Liu Y *et al.*, 2020; Zhu *et al.*, 2020; Breslin *et al.*, 2020; Chen, Zhang *et al.*, 2020). In cases where the neonates were tested positive, the virus

might have been transmitted in other ways, such as with touch, droplets or breast milk (Buonsenso *et al.*, 2020); therefore, the value of universal screening of women admitted for delivery has been supported, especially because many positive women are asymptomatic. Thus, it is of paramount importance to screen pregnant women before labor (Sutton *et al.*, 2020; Fassett *et al.*, 2020).

Caesarean section has been the most common mode of delivery since the start of the COVID-19 epidemic and especially in China, with a rate over 90% (Yang H *et al.*, 2020). A previous systematic review reported that about 75% of the infected women delivered by C-section (Corbett *et al.*, 2020). According to the present systematic review, a substantial proportion of pregnant women with COVID-19 underwent C-section (case reports 82.2%, case series 74.2% and cohort studies 66.0%). Recent guidelines suggest C-section to be considered in cases of severe and critical infections while taking into account possible risks (Royal College of Obstetricians and Gynecologists, 2020). On the other hand, a study from Spain reported that deliveries by C-section were significantly associated with clinical deterioration of positive mothers (Martínez-Perez *et al.*, 2020). Additionally, there is no evidence that the rate of neonatal COVID-19 is lower when the baby is born by C-section (Walker *et al.*, 2020), hence, C-section could be applied in cases where other indications also exist (Ashokka *et al.*, 2020).

In many studies the reason for C-section was not mentioned. It is possible that, because COVID-19 complications are not well-known, especially in the vulnerable group of pregnant women and neonates, increased anxiety of both mothers and doctors might have led to rash decisions. Actually, as already mentioned, C-section was the rule in China and other countries during the first months of the pandemic (Martínez-Perez *et al.*, 2020).

According to Zaigham and Andersson (Zaigham and Andersson, 2020), COVID-19 is a risk factor for increased maternal and perinatal morbidity, probably due to higher rates of preterm birth in mothers with COVID-19 (Allotey *et al.*, 2020). Two maternal deaths and only one neonatal death were reported in a recent systematic review, including 324 pregnant women (Juan *et al.*, 2020). Our study comprised a larger sample with mortality rates ranging from 1% in cohort studies to 5.7% in case reports in mothers, and from 2% in case reports to 3.3% in case series in neonates. Further studies are needed to estimate standardized mortality ratios in COVID-19 pregnant women and their neonates versus pregnant control women, addressing the confounding effects of comorbidities, as pre-existing comorbidities of the mother such as advanced maternal age and high body mass index are potential risk factors for severe COVID-19 during pregnancy (Allotey *et al.*, 2020).

The main limitation of the present systematic review is that most of the currently available studies did

not provide detailed data for participants, probably due to the emergency nature of the subject. Additionally, a substantial amount of evidence was derived from case reports and case series. Moreover, the inadequacy of follow-up periods reduced the validity of cohort studies. Finally, the lack of important data in many studies, such as the positivity of neonates in SARS-CoV-2 testing, mode of delivery and indication for C-section, did not allow extensive analyses.

On the other hand, this systematic review has several strengths as it includes a large sample with detailed data about the mode of labour, morbidity, and vertical transmission. Case reports and case series highlighted important aspects of the disease. Moreover, studies from all continents, except Africa, were included, whereas existing systematic reviews refer mostly to studies derived from China.

In conclusion, according to the present systematic review, vertical transmission of COVID-19 from mother to child is rare. Nevertheless, careful screening of pregnant women seems important in view of adverse health outcomes for the mother and the neonate. Specific guidelines with evidence-based decision algorithms for the mode of delivery in the context of a pregnancy affected by COVID-19 are needed.

Key Points

- Vertical transmission of SARS-CoV-2 from mother to child seems to be rare.
- A substantial proportion of pregnant women with COVID-19 underwent caesarean section.
- Maternal mortality rates ranged from 1% to 5.7% and neonatal mortality from 2% to 3.3%.
- Specific guidelines in the context of a pregnancy affected by COVID-19 are needed.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Ahmed I, Azhar A, Eltaweel N, and Tan BK (2020) First COVID-19 maternal mortality in the UK associated with thrombotic complications. *Br. J. Haematol.* **190** (1), e37–e38. <http://dx.doi.org/10.1111/bjh.16849>
2. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, *et al.* (2020) Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* **370** <http://dx.doi.org/10.1136/bmj.m3320>
3. Alonso Díaz C, López Maestro M, Moral Pumarega MT, Flores Antón B, and Pallás Alonso CR (2020) [First case of neonatal infection due to SARS-CoV-2 in Spain]. *An. Pediatr. Barc. Spain* **2003** **92** (4), 237–238. <http://dx.doi.org/10.1016/j.anpedi.2020.03.002>
4. AlZaghal LA, AlZaghal N, Alomari SO, Obeidat N, Obeidat B, *et al.* (2020) Multidisciplinary team management and cesarean delivery for a Jordanian woman infected with SARS-CoV-2: A case report. *Case Rep. Womens Health* **27**, e00212. <http://dx.doi.org/10.1016/j.crwh.2020.e00212>
5. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, *et al.* (2020) Severe COVID-19 during Pregnancy and Possible Vertical Transmission. *Am. J. Perinatol.* **37** (8), 861–865. <http://dx.doi.org/10.1055/s-0040-1710050>
6. Anderson J, Schauer J, Bryant S, and Graves CR (2020) The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. *Case Rep. Womens Health*, e00221. <http://dx.doi.org/10.1016/j.crwh.2020.e00221>
7. Andrikopoulou M, Madden N, Wen T, Aubey JJ, Aziz A, *et al.* (2020) Symptoms and Critical Illness Among Obstetric Patients With Coronavirus Disease 2019 (COVID-19) Infection. *Obstet. Gynecol.* <http://dx.doi.org/10.1097/AOG.0000000000003996>
8. Ashokka B, Loh M-H, Tan CH, Su LL, Young BE, *et al.* (2020) Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergency cesarean delivery, differential diagnosis in the acutely ill parturient, care of the newborn, and protection of the healthcare personnel. *Am. J. Obstet. Gynecol.* **223** (1), 66–74.e3. <http://dx.doi.org/10.1016/j.ajog.2020.04.005>
9. Baergen RN and Heller DS (2020) Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings. *Pediatr. Dev. Pathol. Off. J. Soc. Pediatr. Pathol. Paediatr. Pathol. Soc.* **23** (3), 177–180. <http://dx.doi.org/10.1177/1093526620925569>
10. Bani Hani DA, Alsharaydeh I, Bataineh AM, Al Athamneh M, Qamileh I, *et al.* (2020) Successful Anesthetic Management in Cesarean Section for Pregnant Woman with COVID-19. *Am. J. Case Rep.* **21**, e925512. <http://dx.doi.org/10.12659/AJCR.925512>
11. Baud D, Greub G, Favre G, Gengler C, Jaton K, *et al.* (2020) Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection. *JAMA* <http://dx.doi.org/10.1001/jama.2020.7233>
12. Berthelot N, Lemieux R, Garon-Bissonnette J, Drouin-Maziade C, Martel É, *et al.* (2020) Uptrend in distress and psychiatric symptomatology in pregnant women during the coronavirus disease 2019 pandemic. *Acta Obstet. Gynecol. Scand.* **99** (7), 848–855. <http://dx.doi.org/10.1111/aogs.13925>
13. Birkeland SA and Kristoffersen K (1980) Lymphocyte transformation with mitogens and antigens during normal human pregnancy: a longitudinal study. *Scand. J. Immunol.* **11** (3), 321–325. <http://dx.doi.org/10.1111/j.1365-3083.1980.tb00240.x>
14. Blauvelt CA, Chiu C, Donovan AL, Pahl M, Shimotake TK, *et al.* (2020) Acute Respiratory Distress Syndrome in a Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19). *Obstet. Gynecol.* **136** (1), 46–51. <http://dx.doi.org/10.1097/AOG.0000000000003949>
15. Blitz MJ, Rochelson B, Minkoff H, Meirowitz N, Prasanna L, *et al.* (2020) Maternal mortality among women with coronavirus disease 2019 admitted to the intensive care unit. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.06.020>
16. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, *et al.* (2020) COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals. *Am. J. Obstet. Gynecol. MFM*, 100118. <http://dx.doi.org/10.1016/j.ajogmf.2020.100118>
17. Breslin N, Baptiste C, Miller R, Fuchs K, Goffman D, *et al.* (2020) Coronavirus disease 2019 in pregnancy: early lessons. *Am. J. Obstet. Gynecol. MFM* **2** (2), 100111. <http://dx.doi.org/10.1016/j.ajogmf.2020.100111>
18. Buonsenso Danilo, Costa S, Sanguinetti M, Cattani P, Posteraro B, *et al.* (2020) Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2. *Am. J. Perinatol.* **37** (8), 869–872. <http://dx.doi.org/10.1055/s-0040-1710541>
19. Buonsenso D, Raffaelli F, Tamburrini E, Biasucci DG, Salvi S, *et al.* (2020) Clinical role of lung ultrasound for diagnosis and monitoring of COVID-19 pneumonia in pregnant women. *Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol.* **56** (1), 106–109. <http://dx.doi.org/10.1002/uog.22055>
20. Campbell KH, Tornatore JM, Lawrence KE, Illuzzi JL, Sussman LS, *et al.* (2020) Prevalence of SARS-CoV-2 Among Patients

- Admitted for Childbirth in Southern Connecticut. *JAMA* <http://dx.doi.org/10.1001/jama.2020.8904>
21. Cao D, Yin H, Chen J, Tang F, Peng M, *et al.* (2020) Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A retrospective study. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* **95**, 294–300. <http://dx.doi.org/10.1016/j.ijid.2020.04.047>
 22. Carosso A, Cosma S, Borella F, Marozio L, Coscia A, *et al.* (2020) Pre-labor anorectal swab for SARS-CoV-2 in COVID-19 pregnant patients: is it time to think about it? *Eur. J. Obstet. Gynecol. Reprod. Biol.* **249**, 98–99. <http://dx.doi.org/10.1016/j.ejogrb.2020.04.023>
 23. Chen H, Guo J, Wang C, Luo F, Yu X, *et al.* (2020) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet Lond. Engl.* **395** (10226), 809–815. [http://dx.doi.org/10.1016/S0140-6736\(20\)30360-3](http://dx.doi.org/10.1016/S0140-6736(20)30360-3)
 24. Chen L, Li Q, Zheng D, Jiang H, Wei Y, *et al.* (2020) Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *N. Engl. J. Med.* **382** (25), e100. <http://dx.doi.org/10.1056/NEJMc2009226>
 25. Chen R, Chen J, and Meng Q-T (2020) Chest computed tomography images of early coronavirus disease (COVID-19). *Can. J. Anaesth. J. Can. Anesth.* **67** (6), 754–755. <http://dx.doi.org/10.1007/s12630-020-01625-4>
 26. Chen R, Zhang Y, Huang L, Cheng B-H, Xia Z-Y, *et al.* (2020) Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients. *Can. J. Anaesth. J. Can. Anesth.* **67** (6), 655–663. <http://dx.doi.org/10.1007/s12630-020-01630-7>
 27. Chen S, Liao E, Cao D, Gao Y, Sun G, *et al.* (2020) Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia. *J. Med. Virol.* <http://dx.doi.org/10.1002/jmv.25789>
 28. Chen Y, Peng H, Wang L, Zhao Y, Zeng L, *et al.* (2020) Infants Born to Mothers With a New Coronavirus (COVID-19). *Front. Pediatr.* **8**, 104. <http://dx.doi.org/10.3389/fped.2020.00104>
 29. Collin J, Byström E, Carnahan A, and Ahrne M (2020) Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. *Acta Obstet. Gynecol. Scand.* **99** (7), 819–822. <http://dx.doi.org/10.1111/aogs.13901>
 30. Cooke WR, Billett A, Gleeson S, Jacques A, Place K, *et al.* (2020) SARS-CoV-2 infection in very preterm pregnancy: Experiences from two cases. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **250**, 259–260. <http://dx.doi.org/10.1016/j.ejogrb.2020.05.025>
 31. Corbett GA, Milin Hehir MP, Lindow SW, and O'connell MP (2020) Health and behavioural changes of pregnant women during the COVID-19 pandemic. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **249**, 96–97. <http://dx.doi.org/10.1016/j.ejogrb.2020.04.022>
 32. De Socio GV, Carne L, Arena S, Troiani S, Benedetti S, *et al.* (2020) Delivery in Asymptomatic Italian Woman with SARS-CoV-2 Infection. *Mediterr. J. Hematol. Infect. Dis.* **12** (1), e2020033. <http://dx.doi.org/10.4084/MJHID.2020.033>
 33. Dong L, Tian J, He S, Zhu C, Wang J, *et al.* (2020) Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn. *JAMA* <http://dx.doi.org/10.1001/jama.2020.4621>
 34. Dong Y, Chi X, Hai H, Sun L, Zhang M, *et al.* (2020) Antibodies in the breast milk of a maternal woman with COVID-19. *Emerg. Microbes Infect.* **9** (1), 1467–1469. <http://dx.doi.org/10.1080/22221751.2020.1780952>
 35. Dória M, Peixinho C, Laranjo M, Mesquita Varejão A, and Silva PT (2020) Covid-19 during pregnancy: A case series from an universally tested population from the north of Portugal. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **250**, 261–262. <http://dx.doi.org/10.1016/j.ejogrb.2020.05.029>
 36. Du Y, Wang L, Wu G, Lei X, Li W, *et al.* (2020) Anesthesia and protection in an emergency cesarean section for pregnant woman infected with a novel coronavirus: case report and literature review. *J. Anesth.* **34** (4), 613–618. <http://dx.doi.org/10.1007/s00540-020-02796-6>
 37. Durankuş F and Aksu E (2020) Effects of the COVID-19 pandemic on anxiety and depressive symptoms in pregnant women: a preliminary study. *J. Matern.-Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet.*, 1–7. <http://dx.doi.org/10.1080/14767058.2020.1763946>
 38. Emeruwa UN, Ona S, Shaman JL, Turitz A, Wright JD, *et al.* (2020) Associations Between Built Environment, Neighborhood Socioeconomic Status, and SARS-CoV-2 Infection Among Pregnant Women in New York City. *JAMA* <http://dx.doi.org/10.1001/jama.2020.11370>
 39. Fan C, Lei D, Fang C, Li C, Wang M, *et al.* (2020) Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* <http://dx.doi.org/10.1093/cid/ciaa226>
 40. Fassett MJ, Lurvey LD, Yasumura L, Nguyen M, Colli JJ, *et al.* (2020) Universal SARS-CoV-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization. *Am. J. Perinatol.* **37** (11), 1110–1114. <http://dx.doi.org/10.1055/s-0040-1714060>
 41. Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, *et al.* (2020) Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis. *BJOG Int. J. Obstet. Gynaecol.* <http://dx.doi.org/10.1111/1471-0528.16278>
 42. Fontanella F, Hannes S, Keating N, Martyn F, Browne I, *et al.* (2020) COVID-19 infection during the third trimester of pregnancy: Current clinical dilemmas. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **251**, 268–271. <http://dx.doi.org/10.1016/j.ejogrb.2020.05.053>
 43. Fox NS and Melka S (2020) COVID-19 in Pregnant Women: Case Series from One Large New York City Obstetrical Practice. *Am. J. Perinatol.* **37** (10), 1002–1004. <http://dx.doi.org/10.1055/s-0040-1712529>
 44. Gagliardi L, Danieli R, Suriano G, Vaccaro A, Tripodi G, *et al.* (2020) Universal severe acute respiratory syndrome coronavirus 2 testing of pregnant women admitted for delivery in 2 Italian regions. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.05.017>
 45. Gidlöf S, Savchenko J, Brune T, and Josefsson H (2020) COVID-19 in pregnancy with comorbidities: More liberal testing strategy is needed. *Acta Obstet. Gynecol. Scand.* <http://dx.doi.org/10.1111/aogs.13862>
 46. Goldfarb IT, Clapp MA, Soffer MD, Shook LL, Rushfirth K, *et al.* (2020) Prevalence and Severity of Coronavirus Disease 2019 (COVID-19) Illness in Symptomatic Pregnant and Postpartum Women Stratified by Hispanic Ethnicity. *Obstet. Gynecol.* <http://dx.doi.org/10.1097/AOG.0000000000004005>
 47. Goodnight WH and Soper DE (2005) Pneumonia in pregnancy. *Crit. Care Med.* **33** (10 Suppl), S390–397. <http://dx.doi.org/10.1097/01.ccm.0000182483.24836.66>
 48. Govind A, Essien S, Karthikeyan A, Fakokunde A, Janga D, *et al.* (2020) Re: Novel Coronavirus COVID-19 in late pregnancy: Outcomes of first nine cases in an inner city London hospital. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **251**, 272–274. <http://dx.doi.org/10.1016/j.ejogrb.2020.05.004>
 49. Hantoushadeh S, Shamshirsaz AA, Aleyasin A, Seferovic MD, Aski SK, *et al.* (2020) Maternal death due to COVID-19. *Am. J. Obstet. Gynecol.* **223** (1), 109.e1–109.e16. <http://dx.doi.org/10.1016/j.ajog.2020.04.030>
 50. Hong L, Smith N, Keerthy M, Lee-Griffith M, Garcia R, *et al.* (2020) Severe COVID-19 infection in pregnancy requiring intubation without preterm delivery: A case report. *Case Rep. Womens Health*, e00217. <http://dx.doi.org/10.1016/j.crwh.2020.e00217>
 51. Hu X, Gao J, Luo X, Feng L, Liu W, *et al.* (2020) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus

- Disease 2019 (COVID-19) Pneumonia. *Obstet. Gynecol.* **136** (1), 65–67. <http://dx.doi.org/10.1097/AOG.00000000000003926>
52. Huang J-W, Zhou X-Y, Lu S-J, Xu Y, Hu J-B, *et al.* (2020) Dialectical behavior therapy-based psychological intervention for woman in late pregnancy and early postpartum suffering from COVID-19: a case report. *J. Zhejiang Univ. Sci. B* **21** (5), 394–399. <http://dx.doi.org/10.1631/jzus.B2010012>
 53. Huang W, Zhao Z, He Z, Liu S, Wu Q, *et al.* (2020) Unfavorable outcomes in pregnant patients with COVID-19. *J. Infect.* <http://dx.doi.org/10.1016/j.jinf.2020.05.014>
 54. Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, *et al.* (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int. J. Infect. Dis.* **91**, 264–266. <http://dx.doi.org/10.1016/j.ijid.2020.01.009>
 55. Ifdil I, Fadli RP, Gusmaliza B, and Putri YE (2020) Mortality and psychological stress in pregnant and postnatal women during COVID-19 outbreak in West Sumatra, Indonesia. *J. Psychosom. Obstet. Gynaecol.*, 1–2. <http://dx.doi.org/10.1080/0167482X.2020.1779216>
 56. Iqbal SN, Overcash R, Mokhtari N, Saeed H, Gold S, *et al.* (2020) An Uncomplicated Delivery in a Patient with Covid-19 in the United States. *N. Engl. J. Med.* **382** (16), e34. <http://dx.doi.org/10.1056/NEJMc2007605>
 57. Jin Y-H, Cai L, Cheng Z-S, Cheng H, Deng T, *et al.* (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Mil. Med. Res.* **7** (1), 4. <http://dx.doi.org/10.1186/s40779-020-0233-6>
 58. Juan J, Gil MM, Rong Z, Zhang Y, Yang H, *et al.* (2020) Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: systematic review. *Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol.* **56** (1), 15–27. <http://dx.doi.org/10.1002/uog.22088>
 59. Juusela A, Nazir M, and Gimovsky M (2020) Two cases of coronavirus 2019-related cardiomyopathy in pregnancy. *Am. J. Obstet. Gynecol. MFM*, 100113. <http://dx.doi.org/10.1016/j.ajogmf.2020.100113>
 60. Kalafat E, Yaprak E, Cinar G, Varli B, Ozisik S, *et al.* (2020) Lung ultrasound and computed tomographic findings in pregnant woman with COVID-19. *Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol.* <http://dx.doi.org/10.1002/uog.22034>
 61. Kayem G, Lecarpentier E, Deruelle P, Bretelle F, Azria E, *et al.* (2020) A snapshot of the Covid-19 pandemic among pregnant women in France. *J. Gynecol. Obstet. Hum. Reprod.*, 101826. <http://dx.doi.org/10.1016/j.jogoh.2020.101826>
 62. Kelly JC, Dombrowski M, O'neil-Callahan M, Kernberg AS, Frolova AI, *et al.* (2020) False-Negative COVID-19 Testing: Considerations in Obstetrical Care. *Am. J. Obstet. Gynecol. MFM*, 100130. <http://dx.doi.org/10.1016/j.ajogmf.2020.100130>
 63. Khalil A, Hill R, Ladhani S, Pattison K, and O'Brien P (2020) Severe acute respiratory syndrome coronavirus 2 in pregnancy: symptomatic pregnant women are only the tip of the iceberg. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.05.005>
 64. Khan S, Peng L, Siddique R, Nabi G, Nawsherwan null, *et al.* (2020) Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. *Infect. Control Hosp. Epidemiol.* **41** (6), 748–750. <http://dx.doi.org/10.1017/ice.2020.84>
 65. Khoury R, Bernstein PS, Debolt C, Stone J, Sutton DM, *et al.* (2020) Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers. *Obstet. Gynecol.* <http://dx.doi.org/10.1097/AOG.0000000000004025>
 66. Kirtzman M, Diambomba Y, Poutanen SM, Malinowski AK, Vlachodimitropoulou E, *et al.* (2020) Probable congenital SARS-CoV-2 infection in a neonate born to a woman with active SARS-CoV-2 infection. *CMAJ Can. Med. Assoc. J. J. Assoc. Med. Can.* **192** (24), E647–E650. <http://dx.doi.org/10.1503/cmaj.200821>
 67. Knight M, Bunch K, Vousden N, Morris E, Simpson N, *et al.* (2020) Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. *BMJ* **369**, m2107. <http://dx.doi.org/10.1136/bmj.m2107>
 68. Kotabagi P, Fortune L, Essien S, Nauta M, and Yoong W (2020) Anxiety and depression levels among pregnant women with COVID-19. *Acta Obstet. Gynecol. Scand.* **99** (7), 953–954. <http://dx.doi.org/10.1111/aogs.13928>
 69. Kuhrt K, McMicking J, Nanda S, Nelson-Piercy C, and Shennan A (2020) Placental abruption in a twin pregnancy at 32 weeks' gestation complicated by COVID-19, without vertical transmission to the babies. *Am. J. Obstet. Gynecol. MFM*, 100135. <http://dx.doi.org/10.1016/j.ajogmf.2020.100135>
 70. Lang G-J and Zhao H (2020) Can SARS-CoV-2-infected women breastfeed after viral clearance? *J. Zhejiang Univ. Sci. B* **21** (5), 405–407. <http://dx.doi.org/10.1631/jzus.B2000095>
 71. Lee DH, Lee J, Kim E, Woo K, Park HY, *et al.* (2020) Emergency cesarean section on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed patient. *Korean J. Anesthesiol.* <http://dx.doi.org/10.4097/kja.20116>
 72. Lee T-Y, Zhong Y, Zhou J, He X, Kong R, *et al.* (2020) The outbreak of coronavirus disease in China: Risk perceptions, knowledge, and information sources among prenatal and postnatal women. *Women Birth J. Aust. Coll. Midwives* <http://dx.doi.org/10.1016/j.wombi.2020.05.010>
 73. Li J, Wang Y, Zeng Y, Song T, Pan X, *et al.* (2020) Critically ill pregnant patient with COVID-19 and neonatal death within two hours of birth. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* **150** (1), 126–128. <http://dx.doi.org/10.1002/ijgo.13189>
 74. Li N, Han L, Peng M, Lv Y, Ouyang Y, *et al.* (2020) Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* <http://dx.doi.org/10.1093/cid/ciaa352>
 75. Li Y, Zhao R, Zheng S, Chen X, Wang J, *et al.* (2020) Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. *Emerg. Infect. Dis.* **26** (6) <http://dx.doi.org/10.3201/eid2606.200287>
 76. Liao J, He X, Gong Q, Yang L, Zhou C, *et al.* (2020) Analysis of vaginal delivery outcomes among pregnant women in Wuhan, China during the COVID-19 pandemic. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* **150** (1), 53–57. <http://dx.doi.org/10.1002/ijgo.13188>
 77. Liao X, Yang Huan, Kong J, and Yang Hongbing (2020) Chest CT Findings in a Pregnant Patient with 2019 Novel Coronavirus Disease. *Balk. Med. J.* **37** (4), 226–228. <http://dx.doi.org/10.4274/balkanmedj.galenos.2020.2020.3.89>
 78. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, *et al.* (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* **62**, e1–34.
 79. Liu D, Li L, Wu X, Zheng D, Wang J, *et al.* (2020) Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. *AJR Am. J. Roentgenol.*, 1–6. <http://dx.doi.org/10.2214/AJR.20.23072>
 80. Liu H, Liu F, Li J, Zhang T, Wang D, *et al.* (2020) Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children. *J. Infect.* **80** (5), e7–e13. <http://dx.doi.org/10.1016/j.jinf.2020.03.007>
 81. Liu W, Wang J, Li W, Zhou Z, Liu S, *et al.* (2020) Clinical characteristics of 19 neonates born to mothers with COVID-19. *Front. Med.* **14** (2), 193–198. <http://dx.doi.org/10.1007/s11684-020-0772-y>
 82. Liu Y, Chen H, Tang K, and Guo Y (2020) Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. *J. Infect.* <http://dx.doi.org/10.1016/j.jinf.2020.02.028>

83. Lokken EM, Walker CL, Delaney S, Kachikis A, Kretzer NM, *et al.* (2020) Clinical characteristics of 46 pregnant women with a severe acute respiratory syndrome coronavirus 2 infection in Washington State. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.05.031>
84. London V, McLaren R, Atallah F, Cepeda C, McCalla S, *et al.* (2020) The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. *Am. J. Perinatol.* **37** (10), 991–994. <http://dx.doi.org/10.1055/s-0040-1712164>
85. Lowe B and Bopp B (2020) COVID-19 vaginal delivery - A case report. *Aust. N. Z. J. Obstet. Gynaecol.* **60** (3), 465–466. <http://dx.doi.org/10.1111/ajo.13173>
86. Lu D, Sang L, Du S, Li T, Chang Y, *et al.* (2020) Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission. *J. Med. Virol.* <http://dx.doi.org/10.1002/jmv.25927>
87. Lucarelli E, Behn C, Lashley S, Smok D, Benito C, *et al.* (2020) Mechanical Ventilation in Pregnancy Due to COVID-19: A Cohort of Three Cases. *Am. J. Perinatol.* **37** (10), 1066–1069. <http://dx.doi.org/10.1055/s-0040-1713664>
88. Lyra J, Valente R, Rosário M, and Guimarães M (2020) Cesarean Section in a Pregnant Woman with COVID-19: First Case in Portugal. *Acta Med. Port.* **33** (6), 429–431. <http://dx.doi.org/10.20344/amp.13883>
89. Martinelli I, Ferrazzi E, Ciavarella A, Erra R, Iurlaro E, *et al.* (2020) Pulmonary embolism in a young pregnant woman with COVID-19. *Thromb. Res.* **191**, 36–37. <http://dx.doi.org/10.1016/j.thromres.2020.04.022>
90. Martínez-Perez O, Vouga M, Cruz Melguizo S, Forcen Acebal L, Panchaud A, *et al.* (2020) Association Between Mode of Delivery Among Pregnant Women With COVID-19 and Maternal and Neonatal Outcomes in Spain. *JAMA* <http://dx.doi.org/10.1001/jama.2020.10125>
91. Masjoudi M, Aslani A, Khazaeeian S, and Fathnezhad-Kazemi A (2020) Explaining the experience of prenatal care and investigating the association between psychological factors with self-care in pregnant women during COVID-19 pandemic: a mixed method study protocol. *Reprod. Health* **17** (1), 98. <http://dx.doi.org/10.1186/s12978-020-00949-0>
92. McLaren RA, London V, Atallah F, McCalla S, Haberman S, *et al.* (2020) Delivery for respiratory compromise among pregnant women with coronavirus disease 2019. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.05.035>
93. Mehta H, Ivanovic S, Cronin A, VanBrunt L, Mistry N, *et al.* (2020) Novel coronavirus-related acute respiratory distress syndrome in a patient with twin pregnancy: A case report. *Case Rep. Womens Health*, e00220. <http://dx.doi.org/10.1016/j.crwh.2020.e00220>
94. Mendoza M, Garcia-Ruiz I, Maiz N, Rodo C, Garcia-Manau P, *et al.* (2020) Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. *BJOG Int. J. Obstet. Gynaecol.* <http://dx.doi.org/10.1111/1471-0528.16339>
95. Miller ES, Grobman WA, Sakowicz A, Rosati J, and Peaceman AM (2020) Clinical Implications of Universal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Pregnancy. *Obstet. Gynecol.* <http://dx.doi.org/10.1097/AOG.0000000000003983>
96. Mohammadi S, Abouzaripour M, Hesam Shariati N, and Hesam Shariati MB (2020) Ovarian vein thrombosis after coronavirus disease (COVID-19) infection in a pregnant woman: case report. *J. Thromb. Thrombolysis* <http://dx.doi.org/10.1007/s11239-020-02177-6>
97. Nesr G, Garnett C, Bailey C, and Arami S (2020) Immune thrombocytopenia flare with mild COVID-19 infection in pregnancy: A case report. *Br. J. Haematol.* <http://dx.doi.org/10.1111/bjh.16928>
98. Ng O-T, Marimuthu K, Chia P-Y, Koh V, Chiew CJ, *et al.* (2020) SARS-CoV-2 Infection among Travelers Returning from Wuhan, China. *N. Engl. J. Med.* **382** (15), 1476–1478. <http://dx.doi.org/10.1056/NEJMc2003100>
99. Oh J, Kim E, Kim H, Lee S-A, Lee KH, *et al.* (2020) Infection control of operating room and anesthesia for cesarean section during pandemic Coronavirus disease-19 (COVID-19) outbreak in Daegu, the republic of Korea - 8 cases report. *Korean J. Anesthesiol.* <http://dx.doi.org/10.4097/kja.202004>
100. Ottawa Hospital Research Institute http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 30 September 2020).
101. Panichaya P, Thaweerat W, and Uthaisan J (2020) Prolonged viral persistence in COVID-19 second trimester pregnant patient. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **250**, 263. <http://dx.doi.org/10.1016/j.ejogrb.2020.05.030>
102. Patanè L, Morotti D, Giunta MR, Sigismondi C, Piccoli MG, *et al.* (2020) Vertical transmission of COVID-19: SARS-CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth. *Am. J. Obstet. Gynecol. MFM*, 100145. <http://dx.doi.org/10.1016/j.ajogmf.2020.100145>
103. Penfield CA, Brubaker SG, Limaye MA, Lighter J, Ratner AJ, *et al.* (2020) Detection of SARS-CoV-2 in Placental and Fetal Membrane Samples. *Am. J. Obstet. Gynecol. MFM*, 100133. <http://dx.doi.org/10.1016/j.ajogmf.2020.100133>
104. Peng Z, Wang J, Mo Y, Duan W, Xiang G, *et al.* (2020) Unlikely SARS-CoV-2 vertical transmission from mother to child: A case report. *J. Infect. Public Health* **13** (5), 818–820. <http://dx.doi.org/10.1016/j.jiph.2020.04.004>
105. Pereira A, Cruz-Melguizo S, Adrien M, Fuentes L, Marin E, *et al.* (2020) Clinical course of coronavirus disease-2019 in pregnancy. *Acta Obstet. Gynecol. Scand.* **99** (7), 839–847. <http://dx.doi.org/10.1111/aogs.13921>
106. Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, *et al.* (2020) Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study. *Am. J. Obstet. Gynecol. MFM*, 100134. <http://dx.doi.org/10.1016/j.ajogmf.2020.100134>
107. Piersigilli F, Carkeek K, Hocq C, van Grambezen B, Hubinont C, *et al.* (2020) COVID-19 in a 26-week preterm neonate. *Lancet Child Adolesc. Health* **4** (6), 476–478. [http://dx.doi.org/10.1016/S2352-4642\(20\)30140-1](http://dx.doi.org/10.1016/S2352-4642(20)30140-1)
108. Qadri F and Mariona F (2020) Pregnancy affected by SARS-CoV-2 infection: a flash report from Michigan. *J. Matern.-Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet.*, 1–3. <http://dx.doi.org/10.1080/14767058.2020.1765334>
109. Qiancheng X, Jian S, Lingling P, Lei H, Xiaogan J, *et al.* (2020) Coronavirus disease 2019 in pregnancy. *Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis.* **95**, 376–383. <http://dx.doi.org/10.1016/j.ijid.2020.04.065>
110. Rabice SR, Altshuler PC, Bovet C, Sullivan C, and Gagnon AJ (2020) COVID-19 infection presenting as pancreatitis in a pregnant woman: A case report. *Case Rep. Womens Health* **27**, e00228. <http://dx.doi.org/10.1016/j.crwh.2020.e00228>
111. Royal College of Obstetricians and Gynecologists, <https://www.rcog.org.uk/globalassets/documents/guidelines/2020-07-24-coronavirus-covid-19-infection-in-pregnancy.pdf>
112. Suzuki S (2020) Psychological status of postpartum women under the COVID-19 pandemic in Japan. *J Matern Fetal Neonatal Med* <https://pubmed.ncbi.nlm.nih.gov/32423262/> (accessed 27 July 2020).
113. Savasi VM, Parisi F, Patanè L, Ferrazzi E, Frigerio L, *et al.* (2020) Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19). *Obstet. Gynecol.* <http://dx.doi.org/10.1097/AOG.0000000000003979>
114. Schnettler WT, Al Ahwel Y, and Suhag A (2020) Severe ARDS in COVID-19-infected pregnancy: obstetric and intensive care considerations. *Am. J. Obstet. Gynecol. MFM*, 100120. <http://dx.doi.org/10.1016/j.ajogmf.2020.100120>
115. Schwartz DA and Graham AL (2020) Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and

- Other Human Coronavirus Infections. *Viruses* **12** (2) <http://dx.doi.org/10.3390/v12020194>
116. Sentilhes L, De Marcillac F, Jouffriau C, Kuhn P, Thuet V, *et al.* (2020) Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.06.022>
 117. Shanes ED, Mithal LB, Otero S, Azad HA, Miller ES, *et al.* (2020) Placental Pathology in COVID-19. *Am. J. Clin. Pathol.* **154** (1), 23–32. <http://dx.doi.org/10.1093/ajcp/aqaa089>
 118. Silverstein JS, Limaye MA, Brubaker SG, Roman AS, Bautista J, *et al.* (2020) Acute Respiratory Decompensation Requiring Intubation in Pregnant Women with SARS-CoV-2 (COVID-19). *AJP Rep.* **10** (2), e169–e175. <http://dx.doi.org/10.1055/s-0040-1712925>
 119. Sinkey RG, Rajapreyar I, Robbins LS, Dionne-Odom J, Pogwizd SM, *et al.* (2020) Heart Failure with Preserved Ejection Fraction in a Postpartum Patient with Superimposed Preeclampsia and COVID-19. *AJP Rep.* **10** (2), e165–e168. <http://dx.doi.org/10.1055/s-0040-1712926>
 120. Sutton D, Fuchs K, D'Alton M, and Goffman D (2020) Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *N. Engl. J. Med.* **382** (22), 2163–2164. <http://dx.doi.org/10.1056/NEJMc2009316>
 121. Taghizadieh A, Mikaeili H, Ahmadi M, and Valizadeh H (2020) Acute kidney injury in pregnant women following SARS-CoV-2 infection: A case report from Iran. *Respir. Med. Case Rep.* **101090**. <http://dx.doi.org/10.1016/j.rmcr.2020.101090>
 122. Tekbali A, Grünebaum A, Saraya A, McCullough L, Bornstein E, *et al.* (2020) Pregnant vs nonpregnant severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 hospital admissions: the first 4 weeks in New York. *Am. J. Obstet. Gynecol.* **223** (1), 126–127. <http://dx.doi.org/10.1016/j.ajog.2020.04.012>
 123. Vivanti AJ, Vauloup-Fellous C, Prevot S, Zupan V, Suffee C, *et al.* (2020) Transplacental transmission of SARS-CoV-2 infection. *Nat. Commun.* **11** (1), 3572. <http://dx.doi.org/10.1038/s41467-020-17436-6>
 124. Vlachodimitropoulou Koumoutsea E, Vivanti AJ, Shehata N, Benachi A, Le Gouez A, *et al.* (2020) COVID-19 and acute coagulopathy in pregnancy. *J. Thromb. Haemost.* **JTH 18** (7), 1648–1652. <http://dx.doi.org/10.1111/jth.14856>
 125. Walker KF, O'Donoghue K, Grace N, Dorling J, Comeau JL, *et al.* (2020) Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis. *BJOG Int. J. Obstet. Gynaecol.* **127** (11), 1324–1336. <http://dx.doi.org/10.1111/1471-0528.16362>
 126. Wang S, Guo L, Chen L, Liu W, Cao Y, *et al.* (2020) A case report of neonatal COVID-19 infection in China. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* <http://dx.doi.org/10.1093/cid/ciaa225>
 127. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, *et al.* (2020) A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* <http://dx.doi.org/10.1093/cid/ciaa200>
 128. Wang Z, Wang Zhigang, and Xiong G (2020) Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan, China. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* <http://dx.doi.org/10.1002/ijgo.13265>
 129. van Well GTJ, Daalderop LA, Wolfs T, and Kramer BW (2017) Human perinatal immunity in physiological conditions and during infection. *Mol. Cell. Pediatr.* **4** <http://dx.doi.org/10.1186/s40348-017-0070-1>
 130. Wen R, Sun Y, and Xing Q-S (2020) A patient with SARS-CoV-2 infection during pregnancy in Qingdao, China. *J. Microbiol. Immunol. Infect.* *Wei Mian Yu Gan Ran Za Zhi* <http://dx.doi.org/10.1016/j.jmii.2020.03.004>
 131. WHO | WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS). Updated recommendations, October 2004 World Health Organization https://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1/en/ (accessed 7 May 2020).
 132. WHO EMRO | MERS situation update, January 2020 | MERS-CoV | Epidemic and pandemic diseases <http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html> (accessed 7 May 2020).
 133. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, *et al.* (2004) Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am. J. Obstet. Gynecol.* **191** (1), 292–297. <http://dx.doi.org/10.1016/j.ajog.2003.11.019>
 134. Wu C, Yang W, Wu X, Zhang T, Zhao Y, *et al.* (2020) Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women. *Virol. Sin.* **35** (3), 305–310. <http://dx.doi.org/10.1007/s12250-020-00227-0>
 135. Wu X, Sun R, Chen J, Xie Y, Zhang S, *et al.* (2020) Radiological findings and clinical characteristics of pregnant women with COVID-19 pneumonia. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* <http://dx.doi.org/10.1002/ijgo.13165>
 136. Wu Y, Liu C, Dong L, Zhang C, Chen Y, *et al.* (2020) Coronavirus disease 2019 among pregnant Chinese women: case series data on the safety of vaginal birth and breastfeeding. *BJOG Int. J. Obstet. Gynaecol.* <http://dx.doi.org/10.1111/1471-0528.16276>
 137. Wu Yanting, Zhang C, Liu H, Duan C, Li C, *et al.* (2020) Perinatal depressive and anxiety symptoms of pregnant women during the coronavirus disease 2019 outbreak in China. *Am. J. Obstet. Gynecol.* <http://dx.doi.org/10.1016/j.ajog.2020.05.009>
 138. Wu Z, McGoogan JM Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention | *Global Health | JAMA | JAMA Network* <https://jamanetwork.com/journals/jama/fullarticle/2762130> (accessed 6 May 2020).
 139. Xia H, Zhao S, Wu Z, Luo H, Zhou C, *et al.* (2020) Emergency Caesarean delivery in a patient with confirmed COVID-19 under spinal anaesthesia. *Br. J. Anaesth.* **124** (5), e216–e218. <http://dx.doi.org/10.1016/j.bja.2020.02.016>
 140. Xiong X, Wei H, Zhang Z, Chang J, Ma X, *et al.* (2020) Vaginal delivery report of a healthy neonate born to a convalescent mother with COVID--19. *J. Med. Virol.* <http://dx.doi.org/10.1002/jmv.25857>
 141. Xu L, Yang Q, Shi H, Lei S, Liu X, *et al.* (2020) Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates. *Sci. Bull.* <http://dx.doi.org/10.1016/j.scib.2020.04.040>
 142. Yan J, Guo J, Fan C, Juan J, Yu X, *et al.* (2020) Coronavirus disease 2019 in pregnant women: a report based on 116 cases. *Am. J. Obstet. Gynecol.* **223** (1), 111.e1-111.e14. <http://dx.doi.org/10.1016/j.ajog.2020.04.014>
 143. Yang H, Hu B, Zhan S, Yang L-Y, and Xiong G (2020) Effects of SARS-CoV-2 infection on pregnant women and their infants: A retrospective study in Wuhan, China. *Arch. Pathol. Lab. Med.* <http://dx.doi.org/10.5858/arpa.2020-0232-SA>
 144. Yang P, Wang X, Liu P, Wei C, He B, *et al.* (2020) Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. *J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol.* **127**, 104356. <http://dx.doi.org/10.1016/j.jcv.2020.104356>
 145. Yassa M, Birol P, Mutlu AM, Tekin AB, Sandal K, *et al.* (2020a) Lung Ultrasound Can Influence the Clinical Treatment of Pregnant Women With COVID-19. *J. Ultrasound Med. Off. J. Am. Inst. Ultrasound Med.* <http://dx.doi.org/10.1002/jum.15367>
 146. Yassa M, Birol P, Yirmibes C, Usta C, Haydar A, *et al.* (2020b) Near-term pregnant women's attitude toward, concern about and knowledge of the COVID-19 pandemic. *J. Matern.-Fetal Neonatal Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean. Perinat. Soc. Int. Soc. Perinat. Obstet.*, 1–8. <http://dx.doi.org/10.1080/14767058.2020.1763947>
 147. Yilmaz R, Kiliç F, Arican Ş, Hacibeyoğlu G, Süslü H, *et al.* (2020) Anesthetic management for cesarean birth in pregnancy with the novel coronavirus (COVID-19). *J. Clin. Anesth.* **66**, 109921. <http://dx.doi.org/10.1016/j.jclinane.2020.109921>
 148. Yu N, Li W, Kang Q, Xiong Z, Wang S, *et al.* (2020) Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre,

- descriptive study. *Lancet Infect. Dis.* **20** (5), 559–564. [http://dx.doi.org/10.1016/S1473-3099\(20\)30176-6](http://dx.doi.org/10.1016/S1473-3099(20)30176-6)
149. Yu N, Li W, Kang Q, Zeng W, Feng L, *et al.* (2020) No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy. *Lancet Infect. Dis.* [http://dx.doi.org/10.1016/S1473-3099\(20\)30320-0](http://dx.doi.org/10.1016/S1473-3099(20)30320-0)
150. Yu Y, Fan C, Bian J, and YinShen null (2020) Severe COVID-19 in a pregnant patient admitted to hospital in Wuhan. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* **150** (2), 262–263. <http://dx.doi.org/10.1002/ijgo.13232>
151. Zaigham M and Andersson O (2020) Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta Obstet. Gynecol. Scand.* **99** (7), 823–829. <http://dx.doi.org/10.1111/aogs.13867>
152. Zamaniyan M, Ebadi A, Aghajanpoor S, Rahmani Z, Haghshenas M, *et al.* (2020) Preterm delivery, maternal death, and vertical transmission in a pregnant woman with COVID-19 infection. *Prenat. Diagn.* <http://dx.doi.org/10.1002/pd.5713>
153. Zambrano LI, Fuentes-Barahona IC, Bejarano-Torres DA, Bustillo C, Gonzales G, *et al.* (2020) A pregnant woman with COVID-19 in Central America. *Travel Med. Infect. Dis.*, 101639. <http://dx.doi.org/10.1016/j.tmaid.2020.101639>
154. Zeng L, Xia S, Yuan W, Yan K, Xiao F, *et al.* (2020) Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr.* <http://dx.doi.org/10.1001/jamapediatrics.2020.0878>
155. Zeng L-N, Chen L-G, Yang C-M, Zeng L-P, Zhang L-Y, *et al.* (2020) Mental health care for pregnant women in the COVID-19 outbreak is urgently needed. *Women Birth J. Aust. Coll. Midwives* <http://dx.doi.org/10.1016/j.wombi.2020.03.009>
156. Zeng Q-L, Li G-M, Ji F, Ma S-H, Zhang G-F, *et al.* (2020) Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study. *Transbound. Emerg. Dis.* <http://dx.doi.org/10.1111/tbed.13674>
157. Zeng Y, Lin L, Yan Q, Wei W, Xiang Yang B, *et al.* (2020) Update on clinical outcomes of women with COVID-19 during pregnancy. *Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.* **150** (2), 264–266. <http://dx.doi.org/10.1002/ijgo.13236>
158. Zhu H, Wang L, Fang C, Peng S, Zhang L, *et al.* (2020) Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl. Pediatr.* **9** (1), 51–60. <http://dx.doi.org/10.21037/tp.2020.02.06>